206 related articles for article (PubMed ID: 30983385)
1. Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development.
Yen E; Davis JM; Milne CP
Ther Innov Regul Sci; 2019 Sep; 53(5):609-614. PubMed ID: 30983385
[TBL] [Abstract][Full Text] [Related]
2. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
Ren Z; Zajicek A
Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
[TBL] [Abstract][Full Text] [Related]
3. Pediatric Antibacterial and Antifungal Trials From 2007 to 2017.
Thaden JT; Chiswell K; Jaffe I; Bergin SP; Yang WE; Romaine A; Roberts J; Nambiar S; Farley J; Benjamin DK; Smith PB; Tsalik EL
Pediatrics; 2018 Sep; 142(3):. PubMed ID: 30158197
[TBL] [Abstract][Full Text] [Related]
4. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
5. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
Rose K
Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
[TBL] [Abstract][Full Text] [Related]
6. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
Chin WW; Joos A
Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
[TBL] [Abstract][Full Text] [Related]
7. Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation.
Vernon JA; Shortenhaus SH; Mayer MH; Allen AJ; Golec JH
Paediatr Drugs; 2012 Oct; 14(5):283-94. PubMed ID: 22775493
[TBL] [Abstract][Full Text] [Related]
8. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
Breslow LH
Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
[TBL] [Abstract][Full Text] [Related]
9. Issues impacting therapeutic outcomes in pediatric patients: an overview.
Kalra A; Goindi S
Curr Pediatr Rev; 2014; 10(3):184-93. PubMed ID: 25088338
[TBL] [Abstract][Full Text] [Related]
10. Reforming the Orphan Drug Act for the 21st Century.
Sarpatwari A; Kesselheim AS
N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
[No Abstract] [Full Text] [Related]
11. Dermatology Drugs for Children-U.S. Food and Drug Administration Perspective.
Epps RE
Dermatol Clin; 2022 Jul; 40(3):289-296. PubMed ID: 35750412
[TBL] [Abstract][Full Text] [Related]
12. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
13. The Meanings of "Pediatric Drug Development".
Rose K; Grant-Kels JM
Ther Innov Regul Sci; 2019 Nov; 53(6):767-774. PubMed ID: 30526039
[TBL] [Abstract][Full Text] [Related]
14. The pediatric studies initiative: after 15 years have we reached the limits of the law?
Milne CP; Davis J
Clin Ther; 2014 Feb; 36(2):156-62. PubMed ID: 24529287
[TBL] [Abstract][Full Text] [Related]
15. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.
Vinks AA; Emoto C; Fukuda T
Clin Pharmacol Ther; 2015 Sep; 98(3):298-308. PubMed ID: 26073179
[TBL] [Abstract][Full Text] [Related]
16. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
Giacoia GP; Taylor-Zapata P; Zajicek A
Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
[TBL] [Abstract][Full Text] [Related]
17. Neonatal and pediatric oral drug delivery: Hopes and hurdles.
Mfoafo KA; Omidian M; Bertol CD; Omidi Y; Omidian H
Int J Pharm; 2021 Mar; 597():120296. PubMed ID: 33524524
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Off-Label and Unlicensed Drug Use and Its Implications.
Gore R; Chugh PK; Tripathi CD; Lhamo Y; Gautam S
Curr Clin Pharmacol; 2017; 12(1):18-25. PubMed ID: 28322168
[TBL] [Abstract][Full Text] [Related]
19. Industry Perspective of Pediatric Drug Development in the United States: Involvement of the European Union Countries.
Onishi T; Tsukamoto K; Matsumaru N; Waki T
Ther Innov Regul Sci; 2018 Jan; 52(1):49-56. PubMed ID: 29714619
[TBL] [Abstract][Full Text] [Related]
20. Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.
Corriol-Rohou S; Cheung SYA
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S112-S119. PubMed ID: 31502694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
